focus -WSS

focus

author：hotspot 2025-09-30 20:20:18 - browse：145

Illustration of a crowd of people looking toward a cityscape. — Adobe

Few public health challenges have been more daunting and persistent than the opioid crisis, which started because of egregious conduct by opioid manufacturers and now is driven by an influx of fentanyl. In my home state of New Hampshire — which has been at the forefront of this heartbreaking epidemic for more than a decade — too many promising futures have been snatched away. As we look to the next stage of bipartisan efforts to take on this challenge, we must quickly reauthorize and expand the SUPPORT Act, which expired Sept. 30. It laid a new foundation for our response to this epidemic — and now it can be used to increase access to the gold standard of treatment for addiction.

In 2018, we came together across party lines to pass the SUPPORT Act, which established vital infrastructure for communities in New Hampshire and across the country to treat addiction, help people recover, and prevent substance misuse in the first place.

While there are dozens of vital measures in this legislation, one of the most critical provisions helped expand access to medication-assisted treatment, the gold standard of addiction care. Access to this lifesaving medication, buprenorphine, has historically been limited by law and clinician reluctance, fueled by harmful stigmas surrounding addiction treatment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Changes to biosimilar regulatory framework must prioritize patients

focus

WSS

Cancer diagnosis changes perspective doctor, former hospital CEO

Medicare’s new pay boost for primary care is angering specialists

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Publishing genetic code of viruses could cause disaster

FDA reorg will put new emphasis on investigations, sources say

Ukraine and a new approach to mental health in war

leisure time

focus

focus

Novavax promises a turnaround & Lilly roils the obesity market

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Second xenotransplant done with gene

BioMarin wins approval for gene therapy to treat hemophilia A

How AI helped researchers track recovery from depression

Medicare details structure of new drug price negotiation program

Ventyx halts psoriasis drug development after lackluster trial results

Walensky prepares to leave CDC — and Congress — behind

White House drug czar issues call for 'recovery

focus

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Experts study whether long Covid risk adds up with each reinfection

Biotech stock slump in 2023: awaiting the turnaround

Senate HELP committee spars over health care workforce policies

White House drug czar issues call for 'recovery

Medical student insurance fails on mental health care coverage

leisure time

focus

focus

explore